Acute Lymphoblastic Leukemia Clinical Trials
Here are the 6 most popular medical studies for acute lymphoblastic leukemia
Anti-tumor antibiotic, Anti-metabolites
Cladribine, Cytarabine, Mitoxantrone for Lymphoblastic Lymphoma
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
Alkylating agents
IMRT + Chemotherapy + Stem Cell Transplant for Leukemia
This trial is giving IMRT with chemotherapy to patients with relapsed or refractory ALL or AML before a donor stem cell transplant. The aim is to find out the side effects of this treatment and the best dose of IMRT to give, as well as how well the IMRT and chemotherapy work in treating patients.
Popular filter options for acute lymphoblastic leukemia trials
T-Cell Lymphoblastic Leukemia Clinical Trials
View 87 T-Cell Lymphoblastic Leukemia medical studies.
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
ALL Clinical Trials
View 85 ALL medical studies.
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
CD19 Positive Clinical Trials
View 17 CD19 positive medical studies.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
CAR T-cell Therapy
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia
This trial will study the side effects of huJCAR014 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia that have failed other treatments. huJCAR014 CAR-T cells are made in the laboratory by genetically modifying a patient's T cells and may specifically kill cancer cells that have a molecule CD19 on their surfaces. The trial will be conducted in two stages with the first stage focused on finding the right dose and the second stage focused on safety and efficacy.
Philadelphia Chromosome Positive Clinical Trials
View 16 Philadelphia chromosome positive medical studies.
Monoclonal Antibodies
Blinatumomab + Chemotherapy/Dasatinib for Acute Lymphoblastic Leukemia
This trial is studying the side effects and efficacy of blinatumomab and combination chemotherapy or dasatinib and prednisone in treating older patients with acute lymphoblastic leukemia.
Tyrosine Kinase Inhibitor
Imatinib + Chemotherapy for Acute Lymphoblastic Leukemia
This trial is studying the combination of imatinib mesylate with two different chemotherapy regimens to treat patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.
Phase 3 Acute Lymphoblastic Leukemia Clinical Trials
View 96 phase 3 acute lymphoblastic leukemia medical studies.
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
Antimetabolite
Combination Chemotherapy +/− Bortezomib for Lymphoma
This trial is comparing how well two different combination chemotherapies work in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Acute Lymphoblastic Leukemia Clinical Trials With No Placebo
View 96 acute lymphoblastic leukemia medical studies that do not have a placebo group.
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
View More Acute Lymphoblastic Leukemia Trials
See another 69 medical studies focused on acute lymphoblastic leukemia.
Frequently Asked Questions
Introduction to acute lymphoblastic leukemia
What are the top hospitals conducting acute lymphoblastic leukemia research?
When it comes to advancing the treatment options for acute lymphoblastic leukemia (ALL), several top hospitals are at the forefront of groundbreaking clinical trials. Located in Houston, M D Anderson Cancer Center leads the charge with an impressive 16 active ALL trials. While they have not conducted any historical trials specifically for this condition, their dedication to researching and finding new treatments is evident.
In Los Angeles, Children's Hospital Los Angeles is making significant strides with 15 ongoing clinical trials focused on ALL. Similar to M D Anderson, they too have not conducted any previous studies for this specific type of leukemia but remain committed to improving outcomes for patients.
Children's Hospital of Orange County (CHOC) in Orange has been proactive in addressing ALL through research initiatives as well. With 14 active clinical trials currently underway, CHOC recorded its first trial dedicated solely to acute lymphoblastic leukemia in 2019 – a testament to their commitment towards progress and innovation.
Meanwhile, Lucile Packard Children's Hospital Stanford University in Palo Alto boasts an impressive portfolio of 13 active ALL trials without having previously carried out any historical ones themselves. Collaborating efforts continue at Children's National Medical Center located in Washington, where they also have undertaken extensive research endeavors regarding ALL; conducting one trial back in2011 while maintaining a current roster of 13 ongoing studies.
These esteemed institutions represent beacons of hope that tirelessly work toward improved outcomes and novel therapies for children and adults battling acute lymphoblastic leukemia across different regions . By pushing the boundaries through innovative clinical trials and collaborative efforts within these medical centers -we take steps closer each day- we inch closer towards defeating this formidably challenging disease once and forever
Which are the best cities for acute lymphoblastic leukemia clinical trials?
Chicago, Illinois; Las Vegas, Nevada; and New york, New York emerge as the leading cities for acute lymphoblastic leukemia clinical trials. Chicago boasts 51 active trials that focus on treatments like Blinatumomab, Pharmacological Study, and Cyclophosphamide. Similarly, Las Vegas offers 51 ongoing studies exploring therapies such as AKR1C3-activated Prodrug OBI-3424 and Arm A (imatinib mesylate, EsPhALL chemotherapy). In New York City, there are 45 active trials investigating interventions like Arm A (imatinib mesylate, EsPhALL chemotherapy), Pharmacological Study, and brexucabtagene autoleucel. These cities provide patients with numerous opportunities to access cutting-edge clinical research in the field of acute lymphoblastic leukemia.
Which are the top treatments for acute lymphoblastic leukemia being explored in clinical trials?
Clinical trials are actively investigating the top treatments for acute lymphoblastic leukemia (ALL). Among them:
- Inotuzumab ozogamicin: An innovative therapy currently being explored in seven ongoing clinical trials.
- Blinatumomab: A promising treatment option under investigation in six active clinical trials.
- CAR-T cell therapy: Showing great potential, CAR-T cell therapies are being studied in five ongoing clinical trials.
These cutting-edge treatments hold significant promise in improving outcomes for patients with acute lymphoblastic leukemia.
What are the most recent clinical trials for acute lymphoblastic leukemia?
Recent clinical trials for acute lymphoblastic leukemia hold great promise in advancing treatment options for patients. One such trial involves blinatumomab, which has shown encouraging results in Phase 2 studies. Another study investigates the effectiveness of fludarabine, cyclophosphamide, and alemtuzumab as a potential treatment option through both Phase 1 and Phase 2 trials. Additionally, hyper-CVAD combined with calaspargase pegol is being explored in a Phase 1 trial to assess its efficacy against acute lymphoblastic leukemia. Furthermore, an innovative treatment approach utilizing CD19-CAR T cells is currently being investigated in a Phase 1 trial. Lastly, rituximab is undergoing evaluation in a Phase 2 study to determine its benefits for those battling acute lymphoblastic leukemia. These ongoing trials signify significant advancements towards improved outcomes and quality of life for individuals affected by this disease.
What acute lymphoblastic leukemia clinical trials were recently completed?
In July 2019, Pfizer successfully completed a clinical trial investigating the effectiveness of inotuzumab ozogamicin-dose level 2 for acute lymphoblastic leukemia. This recent milestone represents an important step in advancing treatments and improving outcomes for patients with this type of leukemia. The completion of this trial provides valuable insights into the potential benefits and safety profile of inotuzumab ozogamicin-dose level 2, offering hope for individuals battling acute lymphoblastic leukemia.